Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results

Core Insights - Ekso Bionics Holdings, Inc. anticipates record revenues for Q4 2024, estimating total revenue between $5.0 million and $5.1 million, compared to $4.8 million in Q4 2023 [2] - The company has made significant progress in 2024, including initial CMS reimbursement for the Ekso Indego Personal device, which is expected to enhance access for Medicare-covered patients [3] - As of December 31, 2024, estimated cash was $6.5 million, down from $8.6 million a year earlier, with an estimated net cash usage of $1.5 million in operations for Q4 2024 [3] Financial Performance - Total revenue for Q4 2024 is projected to be a record at $5.0 million to $5.1 million, marking an increase from $4.8 million in Q4 2023 [2] - Estimated cash as of December 31, 2024, was $6.5 million, a decrease from $8.6 million at the end of 2023 [3] - The company used approximately $1.5 million of net cash in operations during Q4 2024, slightly less than the $1.6 million used in the same period of 2023 [3] Strategic Developments - The company is focused on expanding its CMS claim pipeline and increasing demand for its flagship EksoNR device as part of its long-term growth strategy [3] - Ekso Bionics is recognized as a leading developer of exoskeleton solutions, enhancing human capabilities in both medical and industrial applications [5]